Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

With nearly 210 million individuals affected by dry eye syndrome globally, the demand for effective treatment solutions has surged significantly. The condition is particularly prevalent among aging ...

If underlying inflammation is present, the prescription eye drop XIIDRA® (lifitegrast ophthalmic solution) 5%, used to treat the signs and symptoms of chronic dry eye by targeting inflammation ...

The mucus comes from the conjunctiva which is the transparent tissue covering the whites of the eye and internal surface of ...

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...

Shire’s potential blockbuster Xiidra (lifitegrast) has been approved in the US for dry eye disease, bouncing back from a rejection by the regulator late last year. Xiidra, in a 5% solution ...

Record Net Revenue at 2,736 million euros, +1.5% Strong contribution to Net Revenue from acquisitions at +2.5% Adjusted EBIT ...